ライフサイエンスコーパス: primary myelofibrosis

1 of those with essential thrombocythemia and primary myelofibrosis.

2 cythemia vera, essential thrombocythemia and primary myelofibrosis.

3 have been devised for myelodysplasia and for primary myelofibrosis.

4 ythemia vera, essential thrombocythemia, and primary myelofibrosis.

5 (MPL)-negative essential thrombocythemia and primary myelofibrosis.

6 ential thrombocythemia and 88% of those with primary myelofibrosis.

7 of those with essential thrombocythemia and primary myelofibrosis.

8 the prototypical myeloproliferative neoplasm primary myelofibrosis.

9 to determine whether the same held true for primary myelofibrosis.

10 vent in a JAK2-V617F knock-in mouse model of primary myelofibrosis.

11 lus) includes 8 risk factors for survival in primary myelofibrosis.

12 ia vera (PV), essential thrombocythemia, and primary myelofibrosis.

13 ythemia vera, essential thrombocythemia, and primary myelofibrosis.

14 ythemia vera, essential thrombocythemia, and primary myelofibrosis.

15 or MPL-mutated essential thrombocytemia and primary myelofibrosis, 2 myeloproliferative neoplasms in

16 hermore, SMRT(mRID) mice develop spontaneous primary myelofibrosis, a chronic, usually idiopathic dis

17 oughly half of essential thrombocythemia and primary myelofibrosis acquire a unique somatic 1849G>T J

18 the challenges inherent in the management of primary myelofibrosis and presents an opportunity to add

19 dysplastic syndrome, acute myeloid leukemia, primary myelofibrosis, and T- and B-cell acute lymphocyt

20 cythemia vera, essential thrombocythemia and primary myelofibrosis are also caused by activated tyros

21 cythemia vera, essential thrombocytosis, and primary myelofibrosis are clonal disorders arising in a

22 tial thrombocythemia, polycythemia vera, and primary myelofibrosis are mainly caused by cardiovascula

23 cythemia vera, essential thrombocythemia and primary myelofibrosis are myeloproliferative neoplasms (

24 Severe congenital neutropenia as well as primary myelofibrosis are rare in infancy.

25 ntial thrombocytosis, polycythemia vera, and primary myelofibrosis--are acquired, clonal hematopoieti

26 In essential thrombocythemia and primary myelofibrosis, CALR mutations and JAK2 and MPL m

27 f patients with essential thrombocythemia or primary myelofibrosis carry a mutation in the Janus kina

28 n be a potential therapeutic target to block primary myelofibrosis disease progression.

29 f of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mec

30 In particular, contributions to primary myelofibrosis from mesenchymal stromal cells (MS

31 cythemia vera, essential thrombocythemia and primary myelofibrosis has diagnostic and pathogenetic im

32 ntial thrombocytosis, polycythemia vera, and primary myelofibrosis has ushered in a new era of scient

33 patients with essential thrombocythemia and primary myelofibrosis) has led the World Health Organiza

34 the bone marrow and spleen of patients with primary myelofibrosis have a mesenchymal phenotype, whic

35 rs, and potentially useful animal models for primary myelofibrosis have been developed.

36 Most patients with primary myelofibrosis have elevated levels of JAK-depend

37 Primary myelofibrosis is a myeloproliferative neoplasm t

38 We conclude that MK in primary myelofibrosis is associated with extremely poor

39 Primary myelofibrosis is characterized by the developmen

40 Primary myelofibrosis is the rarest of the myeloprolifer

41 patients with essential thrombocythemia and primary myelofibrosis, it has been hoped that targeted i

42 Among 200 patients with primary myelofibrosis, karyotype at diagnosis was abnorm

43 Significant disease components include primary myelofibrosis, leukemia, histiocytic sarcoma, an

44 The latter line of mice also developed primary myelofibrosis-like symptoms as they aged.

45 Smad2 levels were intrinsically increased in primary myelofibrosis-MSC along with enhanced expression

46 Primary myelofibrosis-MSC overexpressed heparin-binding

47 From 2007 to 2011, 66 patients with primary myelofibrosis or myelofibrosis (MF) preceded by

48 Primary myelofibrosis or myelofibrotic transformation pr

49 is study, we show that bone marrow MSCs from primary myelofibrosis patients exhibit unique molecular

50 n complements DIPSS-plus in the selection of primary myelofibrosis patients for high-risk treatment a

51 matopoietic and stromal cell compartments in primary myelofibrosis patients may heighten therapeutic

52 Among 793 primary myelofibrosis patients seen at our institution,

53 The limited effects of current treatments of primary myelofibrosis (PM) led us to prospectively evalu

54 spectrum of plasma cytokine abnormalities in primary myelofibrosis (PMF) and examines their phenotypi

55 Primary myelofibrosis (PMF) and polycythemia vera (PV) a

56 Essential thrombocythemia (ET) and primary myelofibrosis (PMF) are chronic diseases charact

57 vera (PV), essential thombocytosis (ET), and primary myelofibrosis (PMF) as pathogenetically related

58 Treatment of polycythemia vera (PV) and primary myelofibrosis (PMF) CD34(+) cells with low doses

59 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-nega

60 Furthermore, even though primary myelofibrosis (PMF) has a markedly worse prognos

61 Patients with primary myelofibrosis (PMF) have substantially reduced l

62 Primary myelofibrosis (PMF) is a clonal hematologic mali

63 Primary myelofibrosis (PMF) is a fatal neoplastic diseas

64 Primary myelofibrosis (PMF) is a myeloproliferative neop

65 Primary myelofibrosis (PMF) is characterized by bone mar

66 Primary myelofibrosis (PMF) is characterized by fibrosis

67 sporadic essential thrombocythemia (ET) and primary myelofibrosis (PMF) lacking JAK2 and MPL mutatio

68 Because primary myelofibrosis (PMF) originates at the level of t

69 system for transplantation-age patients with primary myelofibrosis (PMF) that integrates clinical, cy

70 tional Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses five risk factors to pr

71 ia vera, essential thrombocythemia (ET), and primary myelofibrosis (PMF) whereas CALR and MPL mutants

72 ythemia (ET) compared with early/prefibrotic primary myelofibrosis (PMF) with presenting thrombocythe

73 designed to define neoplastic stem cells of primary myelofibrosis (PMF), a myeloproliferative neopla

74 longer duration than in patients with PV and primary myelofibrosis (PMF), and that "triple negative"

75 ntial thrombocythemia, polycythemia vera and primary myelofibrosis (PMF), are a heterogeneous group o

76 s the only curative option for patients with primary myelofibrosis (PMF), but information on its net

77 ients with essential thrombocythemia (ET) or primary myelofibrosis (PMF), first investigating a cohor

78 ck of major improvements in the treatment of primary myelofibrosis (PMF), there are recent indication

79 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

80 ients with essential thrombocythemia (ET) or primary myelofibrosis (PMF).

81 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

82 rotein 3) in mice leads to an MPN resembling primary myelofibrosis (PMF).

83 es reliable risk assessment in patients with primary myelofibrosis (PMF).

84 unmutated essential thrombocythemia (ET) and primary myelofibrosis (PMF).

85 ransformation, and survival of patients with primary myelofibrosis (PMF).

86 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

87 cance for SF3B1 mutations in both MDS-RS and primary myelofibrosis (PMF).

88 enotype and progression in 499 patients with primary myelofibrosis (PMF).

89 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

90 ents with essential thrombocythemia (ET) and primary myelofibrosis (PMF).

91 of CD34+ cells is a unique characteristic of primary myelofibrosis (PMF).

92 ot included in current prognostic scores for primary myelofibrosis (PMF).

93 era (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF).

94 oproliferative neoplasms defines 2 stages of primary myelofibrosis (PMF): prefibrotic/early (pre-PMF)

95 es including essential thrombocythemia (ET); primary myelofibrosis (PMF); and MPN, unclassifiable (MP

96 h JAK2 V617F-positive or JAK2 V617F-negative primary myelofibrosis, post-essential thrombocythemia my

97 rrent diagnosis of intermediate or high-risk primary myelofibrosis, post-polycythaemia vera myelofibr

98 19 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibro

99 ythemia vera, essential thrombocythemia, and primary myelofibrosis show an inherent tendency for tran

100 the bone marrow and spleen of patients with primary myelofibrosis show functional and morphologic ch

101 source of a critical osteogenic function in primary myelofibrosis that supports its pathophysiology,

102 t patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK

103 cythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genet

104 f 884 karyotypically annotated patients with primary myelofibrosis, we sought to identify 1 or 2 para

105 nd extramedullary hematopoiesis characterize primary myelofibrosis, which is also associated with bon

106 t patients with essential thrombocythemia or primary myelofibrosis with nonmutated JAK2 and MPL.

107 g patients with essential thrombocythemia or primary myelofibrosis with nonmutated JAK2 or MPL, CALR

108 y acquired mutations in six patients who had primary myelofibrosis without mutations in JAK2 or MPL.